VCYT: Acquisition-driven expansion, strong test growth, and robust evidence fuel portfolio and market leadership
The discussion highlighted a strategic acquisition to expand the bladder cancer portfolio, strong growth in Decipher and Afirma tests, and robust evidence generation supporting clinical adoption. Financial outlook remains positive with stable reimbursement, targeted reinvestment, and a focus on exp…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.